

Amendments to the *Patented Medicines Regulations, 1994*

In our January NEWSletter, we reported that a revised regulatory package was in the final stages of moving forward to Treasury Board Cabinet Committee. As a next step, Board Staff met with Rx&D, the Canadian Generic Pharmaceutical Association and BIOTECanada in February and March to discuss the proposed amendments and how they would be implemented through changes to the various forms patentees are required to file as part of their regulatory reporting requirements. In the context of these various meetings, the

industry raised concerns relating to a few specific proposed amendments implementation of which could have resulted in a significant increase in the regulatory burden of patentees. It also became clear that the amendments as drafted differed from the intention of the Board. As a result, the Board has further considered the matter and a revised regulatory package is being prepared for forwarding to Treasury Board Cabinet Committee for publication in the *Canada Gazette*, Part II. ■

1 877 861-2350

www.pmprb-cepmb.gc.ca